Biotechnology News

Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle)Initial clinical data from Ntrust-1 and Ntrust-2 expected to be...

Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027On...

BRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple...

Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents,...

Discussions with FDA advance toward expected marketing authorization for GraftAssureDxFDA completes current portion of substantive review in a timely mannerFavorable Medicare reimbursement policy...

Envudeucitinib long-term Phase 3 data for treatment of plaque psoriasis, delivering highest reported PASI 100 Skin Clearance among oral therapies

MALVERN, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today...

Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first...

Overname van Ouro Medicines samen met Gilead Sciences afgerond om potentiële first- en best-in-class T-cel-engager verder te ontwikkelen Ten minste €1,6 miljard aan liquide middelen verwacht over te...

SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...